

Supplementary Table 1: Adverse events

	Number of adverse events all grades*	Number of patients n (%)	Number of adverse events grade 4	Number of patients n (%)
Neutropenia	115	50 (78%)	4	4 (6%)
Asthenia	59	51 (80%)	4	1 (2%)
Anemia	56	40 (63%)	3	2 (3%)
Thrombocytopenia	63	32 (50%)	1	1 (2%)
ALT increase	71	40 (63%)	1	1 (2%)
Gamma-GT increase	59	43 (67%)	5	4 (6%)
Decreased appetite	17	14 (22%)	3	1 (2%)
AST increase	69	38 (59%)	0	0 (0%)
Flu-like syndrome	32	31 (48%)	0	0 (0%)
Dry skin	32	30 (47%)	0	0 (0%)
Dysgueusia	28	27 (42%)	0	0 (0%)
Headache	20	18 (28%)	0	0 (0%)
Arthralgia	21	17 (27%)	0	0 (0%)
Pruritus	15	13 (20%)	0	0 (0%)
Nausea	14	14 (22%)	0	0 (0%)
Diarrhea	14	13 (20%)	0	0 (0%)

ALT = alanine aminotransferase. GT = glutamyl-transferase. AST = aspartate aminotransferase.

Data are n (%). Adverse events that occurred in >20% of patients are listed.

Supplementary Table 2: Hematological toxicity and treatment management during the study

	n (%), n=64
Death	0
Grade 4 anemia (< 65 g/L)	2 (3.1%)
EPO use	38 (59.4%)
RBC transfusion	8 (12.5%)
Grade 4 neutropenia (< 0.50 giga/L)	4 (6.3%)
G-CSF use	7 (10.9%)
Grade 4 thrombocytopenia (< 20 giga/L)	1 (1.6%)
TPO-R agonist use	0 (0.0%)
Platelet transfusion	0 (0.0%)
BOC dose reduction	2 (3.1%)
PEG-IFN dose reduction	5 (7.8%)
RBV dose reduction	14 (21.9%)
Treatment interruption	
Week 20 to 24 grade 4 neutropenia	1
Week 68 grade 4 thrombocytopenia	1

EPO = erythropoietin; RBC = red blood cell; G-CSF = granulocyte colony stimulating factor; TPO-R= thrombopoietin receptor; PEG-IFN = pegylated-interferon; RBV = ribavirin.